BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it will be presenting its latest solutions to support the cellular transplant and therapy ecosystem at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® taking place February 15-19 in Orlando, Florida.
“We look forward to sharing our latest advancements in cell therapy monitoring solutions at this year’s Tandem Meetings,” said Reg Seeto, CEO and President of CareDx. “Additionally, we are pleased to share our innovative digital health solutions to address the needs of patient and transplant centers within this ecosystem.”
“We are excited to work with CareDx on AutoCell,” said Dr. Stella Davies, Director, Division of Bone Marrow Transplantation and Immune Deficiency and Professor at Cincinnati Children’s. “CAR-T cells are becoming a treatment of choice in certain childhood leukemias. Precise measurements of CAR-T levels and persistence in patients may allow for better patient management and earlier detection of disease relapse, potentially improving patient outcomes.”
Data being presented:
Meet the Author Poster Sessions, Thursday, February 16, 5:45 – 6:45 pm ET
- Poster 279: AutoCell: High Sensitivity Solution for Autologous CAR-T Cell Therapy Monitoring, Presented by Lily Wong, MS. AutoCell™ is for research use only and may provide a sensitive pharmacokinetics (PK) monitoring solution for patients treated with all FDA approved autologous CAR-Ts to enable earlier risk prediction and patient stratification.
- Poster 585: Business in the Pre-COVID Vs Post-COVID Era, Presented by Chris Boatner, RN, BSBM, BMTCN, CCRC, CCM, CMCN, Clinical Analyst, CareDx.
CareDx is a leading provider of digital health solutions that powerfully link participating transplant centers, healthcare providers, and patients in better navigating the complex transplant journey to improve patient care. CareDx will be hosting a product theatre to describe the latest advancements across its digital health portfolio.
CareDx Digital Product Theatre for Transplant Centers and Patients
CareDx will be showcasing a broad spectrum of digital health solutions that address needs in the cellular transplant and therapy ecosystem, including workflow management, regulatory reporting, medication management, and remote patient management. Key focus areas include:
- Transplant Center Workflow Management Solution with Ottr® Cellular: Designed for hematopoietic cellular transplant and cellular therapy centers.
- Transplant Center Medication Management Solution with MedActionPlan PRO®: Designed to improve medication adherence and simplify medication regimens.
- Remote patient monitoring with AlloHome®: Designed for patient engagement and timely interventions.
- Patient Mobile Health App with AlloCare®: Helps patients track personal health metrics and test results and manage complex medication regimens.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit:www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s presentation of its latest solutions to support the cellular transplant and therapy ecosystem at the 2023 Tandem Meetings (the “Tandem Presentation”). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its Tandem Presentation; risks that the Tandem Meetings, including the activities and events assembled by CareDx, fails to take place on time, invite the speakers, or discuss the topics as stated in this press release; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by CareDx with the SEC on February 24, 2022, the quarterly report on Form 10-Q for the quarter ended March 31, 2022 filed by CareDx with the SEC on May 5, 2022, the quarterly report on Form 10-Q for the quarter ended June 30, 2022 filed by CareDx with the SEC on August 4, 2022, the quarterly report on Form 10-Q for the quarter ended September 30, 2022 filed by CareDx with the SEC on November 3, 2022, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Contacts
Media Relations
Anna Czene
818-731-2203
Investor Relations
Greg Chodaczek
